Gain Therapeutics 开始针对帕金森病药物的 1b 期试验，针对多达 20 名患者。 Gain Therapeutics begins Phase 1b trial for Parkinson's drug, targeting up to 20 patients.

疗法公司已经开始对其药物GT-02287进行1b期临床试验,用于治疗帕金森病 (PD),包括GBA1突变病例. Gain Therapeutics has started a Phase 1b clinical trial for its drug GT-02287 to treat Parkinson's disease (PD), including cases with a GBA1 mutation. 试验将评估药物的安全性和耐受性,在三个月内最多20名参加者将参加试验。 The trial will assess the drug’s safety and tolerability in up to 20 participants over three months. 预计到2025年第二季度末会取得临时结果。 Interim results are expected by the end of the second quarter of 2025. GT-02287通过恢复酶功能和减少与PD有关的症状,在临床预科研究中显示出前景。 GT-02287 has shown promise in preclinical studies by restoring enzyme function and reducing symptoms associated with PD.